Results 281 to 290 of about 966,197 (400)

Effect of α‐human atrial natriuretic peptide on the synthesis of dopamine in the rat kidney [PDF]

, 1992
Patrício Soares‐da‐Silva, Maria Helena Fernandes   +1 more
openalex   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Atrial natiuretic peptid in normal humans: Hemodynamic and renal effects after single and repeated bolus injection [PDF]

, 1989
Ball, P., Brenner, Barry M., Gerzer, R., Kentsch, M., Klohs, S., Lawrenz, R., Müller-Esch, G., Potratz, J., Scriba, Peter Christian   +8 more
core  

Effects of atrial natriuretic peptide on renal function and renin release in the isolated perfused rat kidney.

, 1987
Shosaku Narumi, Toshiyuki Yasui, Mamoru Yoshizawa, Minako Kawamura, Hiromichi Suzuki, Haruyuki Nakane, Takao Saruta   +6 more
openalex   +2 more sources

Increased Plasma Levels of Brain Natriuretic Peptide in Hypertrophic Cardiomyopathy [PDF]

, 1993
Muneo Yoshibayashi, Tetsuro Kamiya, Yoshihiko Saito, Hisayuki Matsuo   +3 more
openalex   +1 more source

Natriuretic peptides and C-reactive protein in in heart failure and malnutrition: a systematic review and meta-analysis. [PDF]

ESC Heart Fail
Prokopidis K, Irlik K, Ishiguchi H, Rietsema W, Lip GYH, Sankaranarayanan R, Isanejad M, Nabrdalik K.   +7 more
europepmc   +1 more source

Human Atrial Natriuretic Peptide

, 1986
A. J. G. Riegger, Eckhard P. Kromer, K. Kochsiek   +2 more
openalex   +1 more source

Atrial natriuretic peptide in stable and decompensated chronic obstructive pulmonary disease. [PDF]

, 1993
K Skwarski, M Lee, Lindsay W. Turnbull, William MacNee   +3 more
openalex   +1 more source

Association of natriuretic peptides and receptor activity with cardio-metabolic health at middle age. [PDF]

Sci Rep
Prickett TCR, Espiner EA, Pearson JF.
europepmc   +1 more source

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis

ESC Heart Failure, EarlyView.
AIM This analysis provides a comparison of the efficacy of initial mono and combination therapy in patients with PAH and cardiovascular comorbidities or with risk factors of HFpEF (heart failure with preserved ejection fractioin).METHOD Data from the European COMPERA registry were used for a matched pair analysis.
Dirk Skowasch, Christine Pausch, Doerte Huscher, David Pittrow, Judith Wede, Fabian Kreimendahl, Stephan Rosenkranz, Stephan Beckmann, Matthias Held, Ekkehard Grünig, H. Ardeschir Ghofrani, Hans Klose, Andris Skride, Michael Halank, Stefan Stadler, Marion Delcroix, Anton Vonk‐Noordegraaf, Ralf Ewert, Grzegorz Kopec, Marius M. Hoeper, Karen M. Olsson   +20 more
wiley   +1 more source